Psychedelic therapies are gaining traction as potential treatments for a wide range of indications, but the structure and delivery of psychedelic therapies are a sharp departure from more traditional models of psychotherapy and pharmacotherapy for psychiatric and other medical disorders. This may be critical to their success. The current volume provides a comprehensive review of the state of the science of psychedelic therapies, including discussion of models and approaches to psychedelic therapies as well as the current status of safety and efficacy data for mood, substance use, trauma, obsessive-compulsive, neurodevelopmental, neurodegenerative disorders, neurological, and inflammatory disorders.

Outlines a comprehensive, evidence-based approach to coordinating psychopharmacological and psychotherapeutic treatments Cognitive Behavioral Psychopharmacology takes an evidence-based approach to demonstrating the advantages of biopsychosocial integration in interventions for the major psychiatric diagnoses. It is the first and only book to translate the current evidence for cognitive behavioral, psychosocial, and pharmacologic approaches to mental health disorders into clear guidance for clinical practice. There is a burgeoning movement in mental health to acknowledge the entire person’s functioning across physical, psychological and social spheres, and to integrate medical as well as psychological and social interventions to address the entire spectrum of presenting problems. This book bridges a gap in the professional mental health literature on the subject of standalone versus combined treatment approaches. It reviews the current state of integrative care, and makes a strong case that optimal outcomes are best achieved by an awareness of how and why the cognitive-behavioral aspects of prescribed medical and psychological interventions influence treatment. Each disorder-specific chapter is authored by a prescriber and psychotherapist team who consider all the evidence around treatments and combinations, providing outcome conclusions and concise tables of recommended front-line interventions. Provides a biopsychsocial perspective that integrates the medical, psychotherapeutic, family, and community aspects of the therapeutic process Brings together and compares the current evidence for and against treatments that combine psychopharmacology and cognitive behavioral psychotherapy for major psychiatric diagnoses Outlines an evidence-based approach to determining which combination of treatments is most appropriate for each of the major psychiatric diagnoses Describes, in a way that is accessible to both prescribers and therapists, when and how cognitive behavioral therapy can be integrated into pharmacotherapy The book will appeal to a wide range of mental health professionals, including psychologists, psychiatrists, clinical social workers, licensed professional counselors, marriage and family therapists, and addictions counselors. It also will be of interest to primary care physicians and nurse practitioners who work side by side with mental health professionals.

The Psychopharmacology of Hallucinogens focuses on the properties, compositions, functions, transformations, and reactions of hallucinogens. The selection first offers information on the biosynthesis and action of hallucinogens in mammals; role of biogenic amines in the actions of monomethoxy-amphetamines; and molecular mechanism of action of hallucinogens. The book then takes a look at the molecular determinants for interaction with the LSD receptor, including biological studies, molecular reactivity, and summation of the molecular polarization complexes. The text examines the progress on the development of a receptor model for hallucinogenic amphetamines; characterization of psychotomimetics; physical identification of hallucinogenic compounds; and aspects of the pharmacology of phencyclidine. The book also underscores the effects of LSD, mescaline, and DMT, including effects on humans, proposed model, and effects of monoamine manipulations. The text also presents analysis of hallucinogens by Pavlovian conditioning, behavioral measures of hallucinogenic behavior, and drug model of hallucinosis. The selection is a dependable reference for readers interested in the study of hallucinogens.

This book provides a research-based overview of the use of psychotropic medications in combination with psychosocial interventions to improve learning, social interactions, and behavioral functioning of children within the school setting. It details implementation strategies for delivering multimodal treatments to school-aged children with psychiatric diagnoses while coordinating services across educational and health service sectors. In addition, it includes case studies on ADHD, conduct disorder, depression, social anxiety, autism spectrum disorder, bipolar disorder, and psychosis, with overviews of treatment plans, targeted goals and behaviors, classroom-based medication evaluation plans, and treatment responses communicated back to the child’s family and physician. The book concludes with an overview of integrated behavioral health and the benefits of care coordination to school-aged children experiencing social, emotional, and behavioral challenges. Topics featured in this text include: Legal, ethical, and professional issues related to the use of psychotropic medications in school-aged populations. Effective medications for treating mood dysregulation disorders in school-aged youth. Medications for internalizing and externalizing disorders. Common side effects of psychotropic medication in school-aged populations. The need to be culturally sensitive when considering treatment plans for school-aged youth. School Psychopharmacology is an essential resource for researchers, graduate students, and other professionals in child and school psychology, social work, psychiatry, psychopharmacology, special and general education, public health, and counseling.

When the first edition of Pediatric Psychopharmacology published in 2002, it filled a void in child and adolescent psychiatry and quickly establishing itself as the definitive text-reference in pediatric psychopharmacology. While numerous short, clinically focused paperbacks have been published since then, no competitors with the scholarly breadth, depth, and luster of this volume have emerged. In the second edition, Christopher Kratochvil, MD, a highly respected expert in pediatric psychopharmacology, joins the outstanding editorial team led by Dr. Martin and Dr. Scahill. In the new edition, the editors streamline the flow of information to reflect the growth in scientific data since the first edition appeared. The overall structure of the book remains the same, with major sections on underlying biology; somatic interventions; assessment and treatment; and special considerations.

Why do social workers need to know about mental health medications? How can social workers best assist clients who are taking medications? What is the social worker's role as part of the interdisciplinary health care team? Answering these questions and more, this comprehensive text discusses the major medications used to treat common mental health conditions and offers guidelines on how to best serve clients who are using them. This new edition provides guidance on many issues that social workers will encounter in practice, including identifying potentially dangerous drug interactions and adverse side effects; improving medication compliance; recognizing the warning signs of drug dependence; and understanding how psychopharmacology can work in conjunction with psychosocial interventions. Complete with case examples, assessment tools, and treatment plans, this book offers practical insight for social work students and social workers serving clients with mental health conditions. New to this edition are expanded discussions of child and adolescent disorders, engaging discussions of how new drugs are created, approved, and marketed, and a new glossary describing over 150 common medications and herbal remedies. Important Topics Discussed: Treatment of common mental health conditions, such as depression, anxiety disorders, schizophrenia, and dementia Taking a comprehensive medication history Understanding medical terminology Avoiding drug misuse, dependence, and overdose

Psychopharmacology of the Developmental Disabilities explores the use of psychotropic and antiepileptic medications in developmentally disabled patients. A distinguished group of international experts offers comprehensive coverage of traditional psychotropic as well as novel pharmacological agents, antiepileptic drugs, and diet and vitamin treatments. Issues related to litigation, measurement of blood levels, tardive dyskinesia, and behavioral pharmacology are discussed in detail. Psychopharmacology of the Developmental Disabilities provides an excellent overview of what is known about psychoactive drugs and an awareness of the principal social and medical issues posed by these agents.